(Q45306078)

English

Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Mamlouk K

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Saracino G

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Berryman RB

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Fay JW

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Pineiro LA

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Vance EA

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

White M

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sandler I

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Agura ED

9

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

0 references

publication date

1 April 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

35

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

747-754

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704871

0 references

Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Fludarabine and Once-Daily Intravenous Busulfan for Allogeneic Bone Marrow Transplantation for Chediak-Higashi Syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Parenteral busulfan: is therapeutic monitoring still warranted?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

The Pathophysiology of Acute Graft-versus-Host Disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

21 January 2018

Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

7 January 2021

based on heuristic

inferred from DOI database lookup

Venoocclusive disease of the liver following bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

7 January 2021

based on heuristic

inferred from DOI database lookup

Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

7 January 2021

based on heuristic

inferred from DOI database lookup

Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetic and metabolic studies of high-dose busulphan in adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704871

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704871

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45306078&oldid=2143385701"